Interferon

Type: Keyphrase
Name: Interferon
First reported 2 hours ago - Updated 53 mins ago - 1 reports

FDA makes adverse drug event data public, but this health IT startup makes it useful

Four times a year, the FDA releases data about all of the adverse drug events that have been reported to the agency over a three-month time period. Drug companies are required to relay reports they receive of unwanted side effects experienced with use ... [Published MedCity News - 2 hours ago]
First reported 2 hours ago - Updated 1 hour ago - 1 reports

A combination of two oral drugs heals the 97% of patients with hepatitis C (16/04/2014)

A phase III clinical trial made in more than one hundred hospitals in the United States and Europe , including the Vall d’Hebron University Hospital , has shown that the combination of two antiviral drugs administered orally for 12 weeks heals patients ... [Published Vall d'Hebron - 2 hours ago]
First reported 6 hours ago - Updated 6 hours ago - 1 reports

Hepatitis C Drug Sales Show Consumers’ Willingness To Pay Premium Prices

Johnson & Johnson ( JNJ ) reported its first quarter financial results for fiscal 2014 (1QFY14) yesterday, in which it beat analysts’ expectations. At a time when the larger pharmaceuticals have continued to report depressed year-over-year (YoY) results, ... [Published Bidness Etc - 6 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Adding interferon to nucleoside antivirals may improve response for people with chronic hepatitis B

A third study, however, did not see abenefit of pegylated interferon following a short course of nucleoside/nucleotideanalogues.Presented by Wei-Wen Su from Changhua Christian Hospital,the NEED trial included 280 people with HBeAg-positive chronic hepatitis ... [Published Aidsmap - 11 hours ago]
First reported 13 hours ago - Updated 12 hours ago - 2 reports

Research and Markets: World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xgx3p4/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" ... [Published Business Wire Health News - 12 hours ago]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Methods of administering interferon gamma to absorb fluid from the subretinal space

Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated ... [Published Free Patents Online - Apr 15 2014]
Entities: Interferon, Invention
First reported Apr 14 2014 - Updated Apr 15 2014 - 3 reports

Hep C drugs to get TGA approval

Two of the new direct-acting antiviral drugs that are revolutionising the treatment of chronic hepatitis C have been recommended for approval in Australia by the Secretary to the Department of Health.Simeprevir, a NS3/4A protease inhibitor, was recommended ... [Published Gastroenterology Update - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

New drug combination proves effective in treating patients with HCV genotype 1

Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical ... [Published News-Medical.Net - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

Oncolytics Biotech Inc. Collaborators Present Preclinical Research on Liver Cancer at UK Oncolytic Virus Conference

SOURCE Oncolytics Biotech Inc.CALGARYResearchers examined REOLYSIN® in panels of both normal and malignant liver cells and administered either REOLYSIN® or saline to SCID mice with HCV-positive HCC xenografts. The aims of the study were to assess interferon ... [Published State Journal - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

EASL 2014: Adding Interferon to Antivirals May Improve Response for Hepatitis B Patients

Details Category: HBV Treatment Published on Monday, 14 April 2014 00:00 Written by Liz HighleymanAdding pegylated interferon to entecavir (Baraclude) led to greater HBV viral load decline and higher likelihood of serological response in HBeAg positive ... [Published HIV and Hepatitis.com - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 2 reports

Medical News Today: Interferon-free therapy for hepatitis C 'cured' 90% of patients

Current ratings for:Interferon-free therapy for hepatitis C 'cured' 90% of patientsRatings require JavaScript to be enabled.Currently, doctors treating hepatitis C patients with cirrhosis (liver scarring) can only offer treatments that rely on the drug ... [Published Bayou Buzz - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

New hope for cirrhosis in hep C patients

PREVIOUSLY untreatable hepatitis C patients with cirrhosis could benefit from a new combination of antiretroviral drugs, a clinical trial suggests.An experimental interferon-free multidrug therapy was well-tolerated and cured hepatitis C infection in ... [Published Medical Observer - Apr 14 2014]

Quotes

"In another aspect, the subject invention concerns a kit for screening substances for antitumor activity comprising cells and a ligand specific for phosphotyrosine-STAT3 protein, wherein the ligand is directly or indirectly associated with a detectable label. Optionally, the kit can further comprise a substrate for carrying out the assay."
According to the news editors, the research concluded: "Adjuvant systemic drugs may be the most promising of all adjuvant modalities in the near future since HCC may be a systemic disease rather than a local disease."
...Thus, she adds, "the use of these drugs will reduce clearly the name of liver transplants caused by cirrhosis"
...information obtained for this patent application, NewsRx journalists also obtained the inventor's summary information for this patent application: "The invention is based at least in part on a feature(s) of PA that is distinct from its Fc binding characteristics and Superantigen properties. This feature confers one or more of the following activities in animals: an ability to re-regulate aberrant process(es) and inhibit tissue damage or reverse at least a portion of existing tissue damage caused by the un-regulated process(es); an ability to re-regulate aberrant or undesirable immune process(es)."

More Content

All (740) | News (614) | Reports (0) | Blogs (105) | Audio/Video (0) | Fact Sheets (3) | Press Releases (13)
sort by: Date | Relevance
Patent Issued for Materials and Methods for Tre... [Published HispanicBusiness.com - 20 mins ago]
Findings from Sun Yat-Sen University in the Are... [Published HispanicBusiness.com - 20 mins ago]
HCV Genotype 3 -- The New Treatment Challenge [Published General Medicine eJournal - 1 hour ago]
A combination of two oral drugs heals the 97% o... [Published Vall d'Hebron - 2 hours ago]
FDA makes adverse drug event data public, but t... [Published MedCity News - 2 hours ago]
PROTALEX : "Protein a Compositions and Methods ... [Published 4 Traders - 3 hours ago]
Knee Deep in the Hoopla - "A Triumph of Medical... [Published Health Care Renewal - 4 hours ago]
Caspase-11 activation requires lysis of pathoge... [Published Free Internet Press - 4 hours ago]
Drug boost for severe hepatitis C sufferers [Published Channel 4 - 5 hours ago]
Promising results for new hepatitis C drugs [Published BootsWebMD - 6 hours ago]
Hepatitis C Drug Sales Show Consumers’ Willingn... [Published Bidness Etc - 6 hours ago]
EASL 2014: Sofosbuvir + Ribavirin Safe and Effe... [Published HIV and Hepatitis.com - 7 hours ago]
Syrian-Armenian soldier killed in Aleppo [Published News.am - 8 hours ago]
Union of Armenians of Ukraine holds special mee... [Published News.am - 8 hours ago]
Adding interferon to nucleoside antivirals may ... [Published Aidsmap - 11 hours ago]
Research and Markets: World Market for Biosimil... [Published Business Wire Health News - 12 hours ago]
World Market for Biosimilars to 2017: EPO, G-CS... [Published Individual.com - 13 hours ago]
Bristol-Myers announces encouraging results fro... [Published Individual.com - 13 hours ago]
Clinic Speak: what happens when you stop taking... [Published Multiple Sclerosis Research - 14 hours ago]
A Case of Metastatic Gastric Neuroendocrine Tum... [Published Sexual Development - 15 hours ago]
US and Turkey parliament leaders discuss Armeni... [Published News.am - 16 hours ago]
ENANTA PHARMACEUTICALS : Posts Detailed Data fr... [Published 4 Traders - 17 hours ago]
Zoological Society of London holds CPD session [Published MRCVS.co.uk - 21 hours ago]
Trial results for AbbVie’s Hepatitis C candidat... [Published Center Watch - 23 hours ago]
The Early Activation of Toll-Like Receptor (TLR... [Published PLoS medicine - Apr 15 2014]
BI rethinks hepatitis business, posts 2013 results [Published Medical Marketing And Media - Apr 15 2014]
C-WORTHy: Novel therapies show promise in patie... [Published Orthopedics Today - Apr 15 2014]
Breaking bad mitochondria [Published EurekAlert! - Apr 15 2014]
J&J’s Pharmaceutical Success Drives Increase in... [Published Washington Post - Apr 15 2014]
Drawing a Ring Around Antiviral Immunity [Published Bioscience Technology Online - Apr 15 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Knee Deep in the Hoopla - "A Triumph of Medical... [Published Health Care Renewal - 4 hours ago]
With the publication of several new articles in the prestigious New England Journal of Medicine, the buzz about Sovaldi (sofosbuvir - Gilead), a new oral treatment of hepatitis C, has become feverish.  The drug had been hailed as near miraculous, and ...
Research and Markets: World Market for Biosimil... [Published Business Wire Health News - 12 hours ago]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xgx3p4/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" ...
Clinic Speak: what happens when you stop taking... [Published Multiple Sclerosis Research - 14 hours ago]
NHS England green-lights switch from natalizumab to fingolimod in MSers at high-risk of PML #MSBlog #MSResearch #ClinicSpeak Interferon-beta, GA or steroids not good enough to prevent rebound activity  #MSBlog #MSResearch #ClinicSpeak "The study below ...
Ledipasvir and Sofosbuvir for Untreated HCV Gen... [Published The New England Journal of Medicine: Gastroente ... - Apr 12 2014]
Although the treatment of patients infected with the hepatitis C virus (HCV) has evolved greatly in recent years, newly approved regimens for the treatment of patients with HCV genotype 1 infection still include weekly injections of recombinant human ...
Bristol-Myers Squibb Presents Phase III Data De... [Published Business Wire Health News - Apr 10 2014]
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir (DCV), a NS5A inhibitor, ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Simeprevir has now been approved in Russia [Published GlobeNewswire: Acquisitions News - Mar 24 2014]
Hemispherx Biopharma Reports Evidence Based Cli... [Published GlobeNewswire: Advertising News - Jan 07 2014]
Genzyme’s Lemtrada™ Approved in Canada for Trea... [Published Genzyme Press Release - Dec 13 2013]
Simeprevir finns nu tillgängligt för hepatit C-... [Published GlobeNewswire: Acquisitions News - Dec 10 2013]
Simeprevir is now available for Hepatitis C pat... [Published GlobeNewswire: Acquisitions News - Dec 10 2013]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.